lansoprazole has been researched along with Argentaffinoma in 3 studies
Lansoprazole: A 2,2,2-trifluoroethoxypyridyl derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS. Lansoprazole is a racemic mixture of (R)- and (S)-isomers.
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 2 (66.67) | 18.2507 |
2000's | 1 (33.33) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Attila, T | 1 |
Santharam, R | 1 |
Blom, D | 1 |
Komorowski, R | 1 |
Koch, TR | 1 |
Arnold, R | 1 |
Haga, Y | 1 |
Nakatsura, T | 1 |
Shibata, Y | 1 |
Sameshima, H | 1 |
Nakamura, Y | 1 |
Tanimura, M | 1 |
Ogawa, M | 1 |
3 other studies available for lansoprazole and Argentaffinoma
Article | Year |
---|---|
Multifocal gastric carcinoid tumor in a patient with pernicious anemia receiving lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anemia, Pernicious; Biopsy, Needle; Carcinoid Tumor; Female | 2005 |
[What are the indications for proton pump inhibitors? R. Arnold, Marburg, elaborates on the clinical aspects of the controversy regarding lansoprazole. Interview by Gerrit Lichtenberg].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Ulcer Agents; Carcinogenicity Tests; Carcinoi | 1994 |
Human gastric carcinoid detected during long-term antiulcer therapy of H2 receptor antagonist and proton pump inhibitor.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Carcinoid Tumor; Famotidine; Hist | 1998 |